Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fMDA-University of California, San Francisco-Plasmodium vivax malaria
- Development stage
- Unknown
- Lead developer
- University of California, San Francisco
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
fMDA-University of California, San Francisco-Plasmodium vivax malaria refers to the focal mass drug administration (fMDA) regimen evaluated in the FLAME (FocaL Mass Drug Administration for Vivax Malaria Elimination) pragmatic cluster-randomized controlled trial. Developed and led by the University of California, San Francisco (UCSF) in the Loreto Department of Peru, this intervention strategy targets the elimination of *Plasmodium vivax* malaria. The regimen consists of a combination of small molecule antimalarials: chloroquine (CQ) paired with either tafenoquine (TQ) or primaquine (PQ). Chloroquine acts as a schizonticide, targeting the erythrocytic (blood) stages of the parasite by interfering with heme detoxification. Tafenoquine and primaquine are 8-aminoquinolines that provide radical cure by targeting dormant liver-stage hypnozoites, thereby preventing the relapses characteristic of *P. vivax* infection. The fMDA strategy involves administering these drugs to high-risk individuals residing within 200 meters of a confirmed index case.
- Other names
- Focal Mass Drug AdministrationFLAME trial regimen
02
Targets
ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on fMDA-University of California, San Francisco-Plasmodium vivax malaria.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fMDA-University of California, San Francisco-Plasmodium vivax malaria.